Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior ant-HER2 treatment regimens. Study Design of the non-interventional study TRACE in Germany and Austria.

A Nusch, M Angerer, M Welslau, C Uleer, J Radosa, D Wrobel, S Noeding, K Apel, J Terhaag, I Tamm, L Bauer, M Balic, D Egle, N Harbeck, V Müller, E Schumacher-Wulf, R de Buhr, M Glasstetter, J Hanselmann, C Hogrefe, N Marschner, K Gratzke, R Bartsch, A Welt.

Oncol Res Treat (2024) 47 (Suppl. 1): 7–283. https://doi.org/10.1159/000535363 Abstract 49, Seite 28

Download
Link